Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2005 Nov-Dec;25(6C):4471-4.

Nitric oxide-releasing medications and colorectal cancer risk: the framingham study.

Author information

1
Department of Health Evaluation Sciences, Penn State College of Medicine, Hershey, PA 17033, USA.

Abstract

BACKGROUND:

The major sources of human exposure to nitric oxide (NO) are medicinal nitrovasodilators that release NO into the vasculature. Experimental NO-donating aspirin also releases NO in a similar manner, and is a potent in vitro inhibitor of colon cancer.

MATERIALS AND METHODS:

The effects of nitrovasodilators on the risk of colorectal cancer was studied in the Framingham Heart and Offspring studies among 145 cases of colorectal cancer and 433 matched controls.

RESULTS:

Eleven percent of controls reported currently using nitroglycerine or other long-lasting nitrates. In conditional logistic regression analysis, the odds ratio (OR) for colorectal cancer associated with nitrovasodilator use was 1.2 (95% confidence interval [CI] 0.6, 2.2). In subgroup analysis, the OR was 0.7 (95% CI 0.2, 2.2) in aspirin users and 1.6 (95% CI 0.8, 3.2) in subjects not taking aspirin.

CONCLUSION:

These data indicate that NO does not change the risk of colorectal cancer.

PMID:
16334128
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center